Taurochenodeoxycholic acid sodium salt
Modify Date: 2024-01-10 15:46:25
Taurochenodeoxycholic acid sodium salt structure
|
Common Name | Taurochenodeoxycholic acid sodium salt | ||
|---|---|---|---|---|
| CAS Number | 6009-98-9 | Molecular Weight | 521.685 | |
| Density | 1.164 g/mL at 25 °C(lit.) | Boiling Point | 215 °C(lit.) | |
| Molecular Formula | C26H44NNaO6S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 195 °F | |
Use of Taurochenodeoxycholic acid sodium saltTaurochenodeoxycholic acid sodium salt (12-Deoxycholyltaurine sodium salt) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties[1][2]. |
| Name | Sodium taurochenodeoxycholate |
|---|---|
| Synonym | More Synonyms |
| Description | Taurochenodeoxycholic acid sodium salt (12-Deoxycholyltaurine sodium salt) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Human Endogenous Metabolite |
| In Vitro | Taurochenodeoxycholic acid dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, Taurochenodeoxycholic acid significantly augments PKC mRNA levels, activities and increases JNK, caspase-3 and caspase-8 mRNA expression levels, activities[1]. |
| In Vivo | Taurochenodeoxycholic acid (0.05, 0.1g/kg) decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2[2]. Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation[3]. Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats[4]. |
| References |
| Density | 1.164 g/mL at 25 °C(lit.) |
|---|---|
| Boiling Point | 215 °C(lit.) |
| Molecular Formula | C26H44NNaO6S |
| Molecular Weight | 521.685 |
| Flash Point | 195 °F |
| Exact Mass | 521.278687 |
| PSA | 135.14000 |
| LogP | 4.52640 |
| Index of Refraction | n20/D 1.558(lit.) |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| Precursor 2 | |
|---|---|
| DownStream 2 | |
|
[Familial amyloid polyneuropathies: therapeutic issues].
Bull. Acad. Natl. Med. 196(7) , 1333-45; discussion 1345-7, (2012) Patients with familial amyloidpolyneuropathies (FAP) require multidisciplinary neurologic and cardiologic management, including specific treatments to control the progression of systemic amyloidogenes... |
|
|
Bile acids repress hypoxia-inducible factor 1 signaling and modulate the airway immune response.
Infect. Immun. 82(9) , 3531-41, (2014) Gastroesophageal reflux (GER) frequently occurs in patients with respiratory disease and is particularly prevalent in patients with cystic fibrosis. GER is a condition in which the duodenogastric cont... |
|
|
Metabolomics reveals novel biomarkers of illegal 5-nitromimidazole treatment in pigs. Further evidence of drug toxicity uncovered.
Food Chem. 199 , 876-84, (2016) The aim of the study was to investigate the potential of a metabolomics platform to distinguish between pigs treated with ronidazole, dimetridazole and metronidazole and non-medicated animals (control... |
| 2-(((3α,5β,7α)-3,7-Dihydroxy-24-oxocholan-24-yl)amino)ethanesulfonic acid monosodium salt |
| Ethanesulfonic acid, 2-[[(3α,5β,7α,8ξ)-3,7-dihydroxy-24-oxocholan-24-yl]amino]-, sodium salt (1:1) |
| Ethanesulfonic acid, 2-(((3α,5β,7α)-3,7-dihydroxy-24-oxocholan-24-yl)amino)-, monosodium salt |
| taurochenodeoxycholic acid sodium salt |
| Sodium 2-{[(3α,5β,7α,8ξ)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonate |
| MFCD00036745 |